United Therapeutics Corporation $UTHR Shares Acquired by IFP Advisors Inc

IFP Advisors Inc raised its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 24.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,164 shares of the biotechnology company’s stock after acquiring an additional 425 shares during the quarter. IFP Advisors Inc’s holdings in United Therapeutics were worth $622,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after acquiring an additional 15,312 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after acquiring an additional 4,145 shares in the last quarter. Assetmark Inc. boosted its position in shares of United Therapeutics by 20.8% during the 1st quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company’s stock worth $159,823,000 after acquiring an additional 89,290 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of United Therapeutics by 22.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock worth $147,278,000 after acquiring an additional 87,664 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after acquiring an additional 146,664 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Morgan Stanley upped their target price on United Therapeutics from $328.00 to $435.00 and gave the company an “equal weight” rating in a research report on Friday. Cantor Fitzgerald upped their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. HC Wainwright upped their target price on United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, Royal Bank Of Canada began coverage on United Therapeutics in a research report on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $457.21.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 261,935 shares of company stock valued at $105,561,472. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 1.5%

UTHR opened at $433.61 on Wednesday. The business has a 50 day moving average price of $377.79 and a two-hundred day moving average price of $325.47. The company has a market cap of $19.56 billion, a PE ratio of 16.92, a P/E/G ratio of 4.80 and a beta of 0.66. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the company earned $5.85 earnings per share. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.